Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD:
DEADLINE:
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Soleno's Phase 3 clinical trial of diazoxide choline extended-release tablets ("DCCR") revealed safety concerns about the drug candidate, which it subsequently downplayed. DCCR suffered from diminished commercial viability. Based on these facts, Soleno's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP?
Join the case to recover your losses.
This press release may be considered
CONTACT:
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/soleno-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--slno-302711877.html
SOURCE